jetcityimage/iStock Editorial via Getty Images More detailed results from Eli Lilly's ( NYSE: LLY ) three-year, phase 3 SURMOUNT-1 study showed that tirzepatide, the active ingredient in its obesity and type 2 diabetes meds, respectively, Wegovy and Ozempic, led to sustained weight loss and diabetes benefits. After three.
Back to Health Page
